EJEMENARE DAUDU: Open Payments
NPI 1245905058 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$451 in 14 payments from 5 companies in 2025. Trend: 2023 $356 · 2024 $111 · 2025 $451
Food & beverage: $451
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 5 | $189 |
| Alkermes, Inc. | 1 | $86 |
| Neurocrine BioSciences, Inc. | 3 | $79 |
| Otsuka America Pharmaceutical, Inc. | 4 | $72 |
| E.R. Squibb & Sons, L.L.C. | 1 | $25 |
Products named: UZEDY, LYBALVI, INGREZZA, ABILIFY ASIMTUFII, COBENFY, ABILIFY MAINTENA, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
